Resources spotlight 3: triple negative breast cancer
OUR SERIES highlighting the library resources held by the royal society of medicine on topics to be discussed at the upcoming breast cancer forum on 14 September – see https://tinyurl.com/y8j5vn94 – concludes with a list of current resources on triple negative breast cancer. See bottom for the list of resources.
Professor Chris Twelves, professor of clinical pharmacology and oncology, Leeds institute of cancer studies and pathology, university of Leeds, will be speaking on this topic, along with brain metastases, at the forum.
Here Chris writes:
Triple negative breast cancer (TNBC) didn’t exist when I trained as an oncologist but has become a major issue now; why is this?
The first reason is that 30 years ago we recognised hormone (ER) receptor positive breast cancer as a distinct entity and had specific hormonal treatment in the form of tamoxifen for these women; now we have new effective hormonal treatments for them. Secondly, we now have another molecular target, HER2, and specific treatment for women whose cancer is HER2 positive. However, those women whose cancers are neither ER nor HER2 positive have not had options for novel, molecularly targeted therapies and their cancers have been especially difficult to treat.
So where are we now, and where are we heading?
- We need to understand that patients with TNBC often feel “negative” because they have difficult cancers
- We also need to acknowledge that many such women are cured of their cancers
- But others aren’t, and if/when their cancers come back we don’t (yet) have as many treatments as for other types of breast cancer.
BUT there are positive signs:
- We now see that certain chemotherapy drugs may be more effective against TNBC
- Some patients with TNBC have inherited (BRCA positive) cancers and new targeted therapies for them are becoming available
- There are also recent encouraging signs that immunotherapy may work in women with TNBC
- WOMEN WITH TNBC CAN BE CURED AT DIAGNOSIS; IF THEIR CANCERS COME BACK THEY CAN ALSO LIVE WITH, AND BE TREATED FOR, BUT NOT (YET) CURED OF THEIR CANCER
-
- There is much more to do
- But the future is NOT all negative for women with TNBC
Pink Ribbon would like to thank the RSM library section, including Beata Coffey, for assistance in compiling the three lists, as well as participating experts professor Gareth Evans and Dr Rahul Deb. The previous two topics were genetics (add link to https://pinkribbon.co/genetics-breast-cancer/) and pathology (add link to https://pinkribbon.co/pathology-resources/)
Drug Treatment in Triple Negative Breast Cancer (TNBC)
SUGIE, T., 2018. Immunotherapy for metastatic breast cancer. Chinese Clinical Oncology, 7(3).
Abstract and full-text available from the publisher’s website: http://cco.amegroups.com/article/view/19854/19896
PARK, J.H., AHN, J. and KIM, S., 2018. How shall we treat early triple-negative breast cancer (TNBC): from the current standard to upcoming immuno-molecular strategies. ESMO open, 3, pp. e000357.
Abstract and full-text available from PubMed Central: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5950702
GUNEY ESKILER, G., CECENER, G., EGELI, U. and TUNCA, B., 2018. Triple negative breast cancer: new therapeutic approaches and BRCA status. APMIS, 126(5), pp. 371-379.
Abstract from the publisher’s website: https://onlinelibrary.wiley.com/doi/abs/10.1111/apm.12836
Full-text available from the RSM Library e-journals collection.
SHACHAR, S.S., JOLLY, T.A., JONES, E. and MUSS, H.B., 2018. Management of Triple-Negative Breast Cancer in Older Patients: How Is It Different? Oncology (Williston Park, N.Y.), 32(2), pp. 58-63.
Abstract and full-text available from the publisher’s website: http://www.cancernetwork.com/oncology-journal/management-triple-negative-breast-cancer-older-patients-how-it-different
TOLBA, M.F. and OMAR, H.A., 2018. Immunotherapy, an evolving approach for the management of triple negative breast cancer: Converting non-responders to responders. Critical reviews in oncology/hematology, 122, pp. 202-207.
Abstract from the publisher’s website: https://www.sciencedirect.com/science/article/pii/S1040842817304213
Full-text available from the RSM Library e-journals collection.
CHALAKUR-RAMIREDDY, N. and PAKALA, S.B., 2018. Combined drug therapeutic strategies for the effective treatment of Triple Negative Breast Cancer. Bioscience reports, 38(1).
Abstract and full-text available from PubMed Central: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5789156
OMARINI, C., GUAITOLI, G., PIPITONE, S., MOSCETTI, L., CORTESI, L., CASCINU, S. and PIACENTINI, F., 2018. Neoadjuvant treatments in triple-negative breast cancer patients: where we are now and where we are going. Cancer management and research, 10, pp. 91-103.
Abstract and full-text available from PubMed Central: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5772398
RABANAL, C., RUIZ, R., NECIOSUP, S. and GOMEZ, H., 2017. Metronomic chemotherapy for non-metastatic triple negative breast cancer: Selection is the key. World journal of clinical oncology, 8(6), pp. 437-446.
Abstract and full-text available from PubMed Central: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5740099
VINTEA, A., VOICULESCU, S., VOICHITOIU, A., TOADER, O. and BURCOS, T., 2017. Triple negative breast cancer – General characteristics and treatment principles. Gineco.eu, 13(4), pp. 169-171.
Abstract and full-text available from the publisher’s website: http://gineco.eu/index.php/arhiv/74362
LOCATELLI, M. and CURIGLIANO, G., 2017. Notch inhibitors and their role in the treatment of triple negative breast cancer: promises and failures. Current opinion in oncology, 29(6), pp. 411-427.
Abstract from the publisher’s website: https://journals.lww.com/co-oncology/Abstract/2017/11000/Notch_inhibitors_and_their_role_in_the_treatment.3.aspx
Full-text available from the RSM Library e-journals collection.
TIAN, Q., DU, P., LI, S., BAI, Z., YANG, Y. and ZENG, J., 2017. Effect of antitumor treatments on triple-negative breast cancer patients: A PRISMA-compliant network meta-analysis of randomized controlled trials. Medicine, 96(45), pp. e8389.
Abstract from the publisher’s website: https://journals.lww.com/md-journal/fulltext/2017/11100/Effect_of_antitumor_treatments_on_triple_negative.17.aspx
Full-text available from the RSM Library e-journals collection.
LI, C., LIM, S., HSU, J.L. and HUNG, M., 2017. Rational combination of immunotherapy for triple negative breast cancer treatment. Chinese Clinical Oncology, 6(5).
Abstract and full-text available from the publisher’s website: http://cco.amegroups.com/article/view/16393/17513
GARMPIS, N., DAMASKOS, C., GARMPI, A., KALAMPOKAS, E., KALAMPOKAS, T., SPARTALIS, E., DASKALOPOULOU, A., VALSAMI, S., KONTOS, M., NONNI, A., KONTZOGLOU, K., PERREA, D., NIKITEAS, N. and DIMITROULIS, D., 2017. Histone Deacetylases as New Therapeutic Targets in Triple-negative Breast Cancer: Progress and Promises. Cancer genomics & proteomics, 14(5), pp. 299-313.
Abstract and full-text available from PubMed Central: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5611517
MUNZONE, E. and COLLEONI, M., 2017. Metronomics in the neoadjuvant and adjuvant treatment of breast cancer. Cancer letters, 400, pp. 259-266.
Abstract from the publisher’s website: https://www.sciencedirect.com/science/article/pii/S0304383517300265
Full-text available from the RSM Library e-journals collection.
JIA, H., TRUICA, C.I., WANG, B., WANG, Y., REN, X., HARVEY, H.A., SONG, J. and YANG, J., 2017. Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects. Drug resistance updates: reviews and commentaries in antimicrobial and anticancer chemotherapy, 32, pp. 1-15.
Abstract from the publisher’s website: https://www.sciencedirect.com/science/article/pii/S1368764617300316
Full-text available from the RSM Library e-journals collection.
NATORI, A., ETHIER, J., AMIR, E. and CESCON, D.W., 2017. Capecitabine in early breast cancer: A meta-analysis of randomised controlled trials. European journal of cancer, 77, pp. 40-47.
Abstract from the publisher’s website: https://www.sciencedirect.com/science/article/pii/S0959804917307906
Full-text available from the RSM Library e-journals collection.
OCANA, A. and PANDIELLA, A., 2017. Targeting oncogenic vulnerabilities in triple negative breast cancer: biological bases and ongoing clinical studies. Oncotarget, 8(13), pp. 22218-22234.
Abstract and full-text available from PubMed Central: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5400659
CASTRELLON, A.B., PIDHORECKY, I., VALERO, V. and RAEZ, L.E., 2017. The Role of Carboplatin in the Neoadjuvant Chemotherapy Treatment of Triple Negative Breast Cancer. Oncology reviews, 11(1), pp. 324.
Abstract and full-text available from PubMed Central: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5365000
COSTA, R., SHAH, A.N., SANTA-MARIA, C., CRUZ, M.R., MAHALINGAM, D., CARNEIRO, B.A., CHAE, Y.K., CRISTOFANILLI, M., GRADISHAR, W.J. and GILES, F.J., 2017. Targeting Epidermal Growth Factor Receptor in triple negative breast cancer: New discoveries and practical insights for drug development. Cancer treatment reviews, 53, pp. 111-119.
Abstract from the publisher’s website: https://www.sciencedirect.com/science/article/pii/S030573721630158X
Full-text available from the RSM Library e-journals collection.
YAO, H., HE, G., YAN, S., CHEN, C., SONG, L., ROSOL, T.J. and DENG, X., 2017. Triple-negative breast cancer: is there a treatment on the horizon? Oncotarget, 8(1), pp. 1913-1924.
Abstract and full-text available from PubMed Central: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5352107
CHEN, G., GUO, Z., LIU, M., YAO, G., DONG, J., GUO, J. and YE, C., 2017. Clinical Value of Capecitabine-Based Combination Adjuvant Chemotherapy in Early Breast Cancer: A Meta-Analysis of Randomized Controlled Trials. Oncology research, 25(9), pp. 1567-1578.
Abstract and full-text available from the publisher’s website: http://www.ingentaconnect.com/content/cog/or/2017/00000025/00000009/art00015
GE, L., TANG, Y., ZHANG, Q., TIAN, J., WANG, X., PIEPER, D., PAN, B., LI, L., LING, J., BING, Z. and YANG, K., 2017. A network meta-analysis on the efficacy of targeted agents in combination with chemotherapy for treatment of advanced/metastatic triple-negative breast cancer. Oncotarget, 8(35), pp. 59539-59551.
Abstract and full-text available from PubMed Central: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5601753
ZHANG, J., FU, F., LIN, Y., CHEN, Y., LU, M., CHEN, M., YANG, P., HUANG, M. and WANG, C., 2017. Evaluating the benefits and adverse effects of an enthracyclinetaxane-capecitabine combined regimen in patients with early breast cancer. Oncotarget, 8(46), pp. 81636-81648.
Abstract and full-text available from PubMed Central: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5655315
WANG, L., XIE, H., ZHOU, H., YAO, W., ZHAO, X. and WANG, Y., 2017. Efficacy of carboplatin-based preoperative chemotherapy for triple-negative breast cancer. A meta-analysis of randomized controlled trials. Saudi medical journal, 38(1), pp. 18-23.
Abstract and full-text available from PubMed Central: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5278059
AUBELE, M., SCHMITT, M., NAPIERALSKI, R., PAEPKE, S., ETTL, J., ABSMAIER, M., MAGDOLEN, V., MARTENS, J., FOEKENS, J.A., WILHELM, O.G. and KIECHLE, M., 2017. The Predictive Value of PITX2 DNA Methylation for High-Risk Breast Cancer Therapy: Current Guidelines, Medical Needs, and Challenges. Disease markers, 2017, pp. 4934608.
Abstract and full-text available from the publisher’s website: https://www.hindawi.com/journals/dm/2017/4934608
